Research ArticleOriginal Research
Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray, Britney A Stottlemyer, Richard D Boyce and Sandra L Kane-Gill
Respiratory Care November 2021, 66 (11) 1739-1745; DOI: https://doi.org/10.4187/respcare.08809
Hyunwoo Kim
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Colin M Pfeiffer
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Matthew P Gray
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Britney A Stottlemyer
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Richard D Boyce
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania.
Sandra L Kane-Gill
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.

References
- 1.↵Forum of International Respiratory Societies. The Global Impact of Respiratory Disease, Second Edition. Sheffield, UK: Forum of International Respiratory Societies; 2017.
- 2.↵
- 3.↵Global Asthma Network Steering Group, Global Asthma Network Study Group. Global Asthma Report 2014. Available at: http://globalasthmanetwork.org/publications/Global_Asthma_Report_2014.pdf. Accessed March 25, 2021.
- 4.↵
- 5.↵
- 6.↵
- Kim D,
- Chen Z,
- Zhou LF,
- Huang SX
- 7.↵
- Raj N,
- Fernandes S,
- Charyulu NR,
- Dubey A,
- G SR,
- Hebbar S
- 8.↵
- 9.↵
- Coleman JJ,
- Pontefract SK
- 10.↵
- Mims JW
- 11.↵
- Vestbo J
- 12.↵AstraZeneca. Symbicort (budesonide and formoterol fumarate dihydrate). Available at: https://www.mysymbicort.com. Accessed May 12, 2021.
- 13.↵GlaxoSmithKline. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder). Available at: https://www.mybreo.com. Accessed May 12, 2021.
- 14.↵GlaxoSmithKline. Advair Diskus (fluticasone propionate and salmeterol inhalation powder). Available at: https://www.advair.com. Accessed May 12, 2021.
- 15.↵
- Banda JM,
- Evans L,
- Vanguri RS,
- Tatonetti NP,
- Ryan PB,
- Shah NH
- 16.↵
- Donohue JF,
- Niewoehner D,
- Brooks J,
- O'Dell D,
- Church A
- 17.↵
- Maltais F,
- Bjermer L,
- Kerwin EM,
- Jones PW,
- Watkins ML,
- Tombs L,
- et al
- 18.↵
- 19.↵
- 20.↵
- Cilli A,
- Bal H,
- Gunen H
- 21.↵FDA Drug Safety Communication. FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). April 15, 2011. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes. Accessed March 1, 2021.
- 22.↵
- Welch HK,
- Kellum JA,
- Kane-Gill S
- 23.
- Gray MP,
- Dziuba G,
- Quach K,
- Wong A,
- Smithburger PL,
- Seybert AL,
- Kane-Gill SL
- 24.↵
- Patel NM,
- Stottlemyer BA,
- Gray MP,
- Boyce RD,
- Kane-Gill SL
- 25.↵
- Arora A,
- Jalali RK,
- Vohora D
In this issue
Respiratory Care
Vol. 66, Issue 11
1 Nov 2021
Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray, Britney A Stottlemyer, Richard D Boyce, Sandra L Kane-Gill
Respiratory Care Nov 2021, 66 (11) 1739-1745; DOI: 10.4187/respcare.08809
Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
Hyunwoo Kim, Colin M Pfeiffer, Matthew P Gray, Britney A Stottlemyer, Richard D Boyce, Sandra L Kane-Gill
Respiratory Care Nov 2021, 66 (11) 1739-1745; DOI: 10.4187/respcare.08809